Association of Ki-67 Expression and Response of Neoadjuvant Chemotherapy in Invasive Breast Cancer Patients in Bandung

Andri Rezano, Chen En Pan, Afrida Aizzatun Istiqomah, Almira Zada


Objective: To analyze the association of Ki-67 expression and response of neoadjuvant chemotherapy in patients with invasive breast cancer.   

Methods: A retrospective observational study on the association of Ki-67 expression and response of neoadjuvant chemotherapy in patients with invasive breast cancer was conducted. This study included twenty-five female patients with invasive breast cancer who met the inclusion criteria. Parameters analyzed were age, tumor size, and immunohistochemical expression of Ki-67. Size of the tumor at pre- and post-neoadjuvant chemotherapy were obtained in cm3 and compared between 3 groups of Ki-67 expression levels. One way ANOVA was used to perform the statistical analysis. 

Results: A significant difference in changes of tumor size for Ki-67 level >20% compared to <14% and 14–20% was seen. Based on the result, neoadjuvant chemotherapy was proven to have similar effects in patients with Ki-67 expression of <14% and 14–20% but less effective in patients with Ki-67 expression of >20%. 

Conclusions: Low to modest expression of Ki-67 was a better biomarker to predict the response of neoadjuvant chemotherapy in patients with invasive breast cancer compared to high expression of Ki-67. However, the cut-off value of 20% could be ideal to predict the outcome of neoadjuvant chemotherapy in patients with invasive breast cancer.


DOI: 10.15850/ijihs.v6n2.1374


Breast cancer, Ki-67, neoadjuvant chemotherapy, invasive breast cancer, tumour.

Full Text:



Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin. 2012;62(1):10–29.

World Health Organization. Cancer country profiles 2013. [cited 2016 Apr 1]. Available from:

Lotsch J, Sipila R, Tasmuth T, Kringel D, Estlander AM, Meretoja T, et al. Machine-learning-derived classifier predicts absence of persistent pain after breast cancer surgery with high accuracy. Breast Cancer Res Treat. 2018;72(12):399–411.

Burcombe RJ, Makris A, Richman PI, Daley FM, Noble S, Pittam M, et al. Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. Br J Cancer. 2005;92(1):147–55.

Ingolf JB, Russalina M, Simona M, Julia R, Gilda S, Bohle RM, et al. Can ki-67 play a role in prediction of breast cancer patients’ response to neoadjuvant chemotherapy? Biomed Res Int [serial on the internet]. 2014 Mar [cited 2017 Aug 7];2014(1):[about 8p.]. Available from:

Inwald EC, Klinkhammer-Schalke M, Hofstädter F, Zeman F, Koller M, Gerstenhauer M, et al. Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat. 2013;139(2):539–52.

Kim KI, Lee KH, Kim TR, Chun YS, Lee TH, Park HK. Ki-67 as a predictor of response to neoadjuvant chemotherapy in breast cancer patients. J Breast Cancer. 2014;17(1):40–6.

Fasching PA, Heusinger K, Haeberle L, Niklos M, Hein A, Bayer CM, et al. Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC Cancer [serial on the internet]. 2011 Nov [cited 2018 Jan 17];11(486):[about 13p.]. Available from:

Gnant M, Thomssen C, Harbeck N. St. Gallen/Vienna 2015: A brief summary of the consensus discussion. Breast Care (Basel). 2015;10(2):124–30.

Tashima R, Nishimura R, Osako T, Nishiyama Y, Okumura Y, Nakano M, et al. Evaluation of an optimal cut-off point for the ki-67 index as a prognostic factor in primary breast cancer: a retrospective study. PLoS One [serial on the internet]. 2015 Jul [cited 2017 Dec 12];10(7):[about 10p.]. Available from:


Article Metrics

Abstract view : 1393 times
PDF - 279 times


This Journal indexed by



Creative Commons License
IJIHS is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License

View My Stats